Osteoarthritis (OA) is a degeneration of the joints, which is characterized by progressive destruction of articular cartilage and articular structures. It is a complex process, which involves multiple changes in joint structure and turnover, and it is the leading cause of disability in the USA. Moreover, the disase is estimated to be the eighth most common cause of disability worldwide.
In a recent report, entitled Stakeholder Opinions: Osteoporosis - Preconceptins, Damage Awareness and Treatments, independent market analyst Datamonitor estimates that 89 million adults in the world's seven major pharmaceutical markets have some form of symptomatic osteoarthritis. The seven markets are France, Germany, Italy, Japan, Spain, the UK and USA. Due to the current widespread nature of the condition, the World Health Organization has declared the current 10-year period, 2000-2010, the "Bone and Joint Decade."
R&D driven by high unmet need and large population
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze